Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Commercialization revenue	$ 40,190	$ 2,020	$ 96,187	$ 3,697
License and collaboration revenue	0	118	0	624
Total revenue	40,190	2,138	96,187	4,321
Costs and operating expenses:
Cost of commercialization revenue	7,602	2,615	14,214	5,726
Research and development expenses	43,924	56,888	122,762	175,185
General and administrative expenses	10,421	12,247	30,446	39,454
Total costs and operating expenses	61,947	71,750	167,422	220,365
Loss from operations	(21,757)	(69,612)	(71,235)	(216,044)
Other income (expense), net:
Interest income	459	1,218	1,513	4,715
Interest expense	(1,183)	(1,395)	(3,598)	(4,109)
Other income (expense), net	555	(27)	617	(234)
Total other income (expense), net	(169)	(204)	(1,468)	372
Loss before provision for (benefit from) income taxes	(21,926)	(69,816)	(72,703)	(215,672)
Provision for (benefit from) income taxes	(17)	(19)	7	4
Net income (loss)	(21,909)	(69,797)	(72,710)	(215,676)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities	36	362	226	1,496
Comprehensive income (loss)	$ (21,873)	$ (69,435)	$ (72,484)	$ (214,180)
Basic net loss per common share	$ (2.93)	$ (16.4)	$ (11.34)	$ (51.27)
Diluted net loss per common share	$ (2.93)	$ (16.4)	$ (11.34)	$ (51.27)
Basic weighted-average shares outstanding	7,466	4,256	6,414	4,207
Diluted weighted-average shares outstanding	7,466	4,256	6,414	4,207